CTOs on the Move

T-Bird Pharma

www.tbirdpharma.com

 
We are T-Bird Pharma Inc., a public company listed on the TSX-V. We are the parent company to Thunderbird Biomedical Inc. Thunderbird is a licensed medical marijuana producer operating within the parameters of Health Canada`s MMPR. Thunderbird obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. T-Bird is the publicly traded parent company of Thunderbird.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tbirdpharma.com
  • Suite 1895 - 1066 West Hastings Street
    Vancouver, BC CAN V6E 3X1
  • Phone: 604.566.9236

Executives

Name Title Contact Details

Similar Companies

Natrol

Natrol, Inc. (Natrol) manufactures and markets dietary supplements, herbal teas, and sports nutrition products under three primary brands: Natrol, Laci Le Beau, and Prolab. Through its Essentially Pure Ingredients (EPI) division, the Company sells

Trimeris

Trimeris is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highfive Vet Wholesale

Automated purchasing for vet clinics | Less mundane tasks. More time for your mission.

PCI Pharma Services

PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)